Unveiling anticancer potential of glibenclamide: Its synergistic cytotoxicity with doxorubicin on cancer cells

[Display omitted] •Glibenclamide interacts with DNA through groove binding.•The spectrometric and electrochemical studies reveal direct interaction of Glibenclamide with DNA.•The interaction between Glibenclamide and B-form of DNA is thermodynamically favorable.•Glibenclamide synergistically enhance...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of pharmaceutical and biomedical analysis 2018-05, Vol.154, p.294-301
Hauptverfasser: Subramaniyam, Nithyananthan, Arumugam, Suyavaran, Ezthupurakkal, Preedia Babu, Ariraman, Subastri, Biswas, Indrani, Muthuvel, Suresh Kumar, Balakrishnan, Aristatile, Alshammari, Ghedeir M., Chinnasamy, Thirunavukkarasu
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 301
container_issue
container_start_page 294
container_title Journal of pharmaceutical and biomedical analysis
container_volume 154
creator Subramaniyam, Nithyananthan
Arumugam, Suyavaran
Ezthupurakkal, Preedia Babu
Ariraman, Subastri
Biswas, Indrani
Muthuvel, Suresh Kumar
Balakrishnan, Aristatile
Alshammari, Ghedeir M.
Chinnasamy, Thirunavukkarasu
description [Display omitted] •Glibenclamide interacts with DNA through groove binding.•The spectrometric and electrochemical studies reveal direct interaction of Glibenclamide with DNA.•The interaction between Glibenclamide and B-form of DNA is thermodynamically favorable.•Glibenclamide synergistically enhances the cytotoxicity of Doxorubicin against HepG2 and A 549 cells. Drug repurposing has been an emerging therapeutic strategy, which involves exploration of a new therapeutic approach for the use of an existing drug. Glibenclamide (Gli) is an anti-diabetic sulfonylurea drug extensively used for the treatment of type-2 diabetes, it has also been shown to possess anti-proliferative effect against several types of tumors. The present study was executed to understand the mechanisms underlying the interaction of Gli with DNA under physiological conditions. The binding mechanism of Gli with DNA was scrutinized by UV–vis absorption spectroscopy and fluorescence emission spectroscopy. The conformational changes and electrochemical properties were analyzed by circular dichroism spectroscopy and cyclic voltammetry. Isothermal titration calorimetry was employed to examine the thermodynamic changes and molecular docking technique used to analyze the interaction mode of Gli with DNA. The spectroscopic studies revealed that Gli interacts with DNA through groove binding mode. Further, isothermal titration calorimetry depicted a stronger mode of interaction favorably groove-binding. Recently, systemic combination therapy has shown significant promise in inhibiting multiple targets simultaneously yielding high therapeutic competence with lesser side effects. With this concern, we intended to study the combined cytotoxicity of Gli with doxorubicin (Dox). The results of MTT assay and acridine orange (AO)/ethidium bromide (EtBr) staining showed synergistic cytotoxicity of Gli + Dox combination on HepG2 & A549 cells. The present study documents the intricate mechanism of Gli–DNA interaction and delivers a multifaceted access for chemotherapy by Gli + Dox combination.
doi_str_mv 10.1016/j.jpba.2018.03.025
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2018013146</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0731708517329448</els_id><sourcerecordid>2018013146</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-195109e22667d0b08c68c5d551f1e891c78a3c9483dc7f6c8ee3362b117e13403</originalsourceid><addsrcrecordid>eNp9kE1vEzEQhi0EomnhD3BAPnLZxWOvPxZxQRXQSpW4UImbteudDY42drCdtvn3OCRw5GSN9byvZh5C3gBrgYF6v2k3u3FoOQPTMtEyLp-RFRgtGq66H8_JimkBjWZGXpDLnDeMMQl995Jc8F4qLTVfkXAfHtAvPqzpEIp3Q3CY6C4WrNOw0DjT9eJHDG4Ztn7CD_S2ZJoPAdPa5xqg7lBiiU_e-XKgj778pFN8imk_1p9AY6DnTofLkl-RF_OwZHx9fq_I_ZfP369vmrtvX2-vP901TkhVGuglsB45V0pPbGTGKePkJCXMgKYHp80gXN8ZMTk9K2cQhVB8BNAIomPiirw79e5S_LXHXOzW5-MGQ8C4z_bojIGATlWUn1CXYs4JZ7tLfjukgwVmj57txh49_8lYJmz1XENvz_37cYvTv8hfsRX4eAKwXvngMdnsfLWIk0_oip2i_1__b3pfkDo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2018013146</pqid></control><display><type>article</type><title>Unveiling anticancer potential of glibenclamide: Its synergistic cytotoxicity with doxorubicin on cancer cells</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Subramaniyam, Nithyananthan ; Arumugam, Suyavaran ; Ezthupurakkal, Preedia Babu ; Ariraman, Subastri ; Biswas, Indrani ; Muthuvel, Suresh Kumar ; Balakrishnan, Aristatile ; Alshammari, Ghedeir M. ; Chinnasamy, Thirunavukkarasu</creator><creatorcontrib>Subramaniyam, Nithyananthan ; Arumugam, Suyavaran ; Ezthupurakkal, Preedia Babu ; Ariraman, Subastri ; Biswas, Indrani ; Muthuvel, Suresh Kumar ; Balakrishnan, Aristatile ; Alshammari, Ghedeir M. ; Chinnasamy, Thirunavukkarasu</creatorcontrib><description>[Display omitted] •Glibenclamide interacts with DNA through groove binding.•The spectrometric and electrochemical studies reveal direct interaction of Glibenclamide with DNA.•The interaction between Glibenclamide and B-form of DNA is thermodynamically favorable.•Glibenclamide synergistically enhances the cytotoxicity of Doxorubicin against HepG2 and A 549 cells. Drug repurposing has been an emerging therapeutic strategy, which involves exploration of a new therapeutic approach for the use of an existing drug. Glibenclamide (Gli) is an anti-diabetic sulfonylurea drug extensively used for the treatment of type-2 diabetes, it has also been shown to possess anti-proliferative effect against several types of tumors. The present study was executed to understand the mechanisms underlying the interaction of Gli with DNA under physiological conditions. The binding mechanism of Gli with DNA was scrutinized by UV–vis absorption spectroscopy and fluorescence emission spectroscopy. The conformational changes and electrochemical properties were analyzed by circular dichroism spectroscopy and cyclic voltammetry. Isothermal titration calorimetry was employed to examine the thermodynamic changes and molecular docking technique used to analyze the interaction mode of Gli with DNA. The spectroscopic studies revealed that Gli interacts with DNA through groove binding mode. Further, isothermal titration calorimetry depicted a stronger mode of interaction favorably groove-binding. Recently, systemic combination therapy has shown significant promise in inhibiting multiple targets simultaneously yielding high therapeutic competence with lesser side effects. With this concern, we intended to study the combined cytotoxicity of Gli with doxorubicin (Dox). The results of MTT assay and acridine orange (AO)/ethidium bromide (EtBr) staining showed synergistic cytotoxicity of Gli + Dox combination on HepG2 &amp; A549 cells. The present study documents the intricate mechanism of Gli–DNA interaction and delivers a multifaceted access for chemotherapy by Gli + Dox combination.</description><identifier>ISSN: 0731-7085</identifier><identifier>EISSN: 1873-264X</identifier><identifier>DOI: 10.1016/j.jpba.2018.03.025</identifier><identifier>PMID: 29567572</identifier><language>eng</language><publisher>England: Elsevier B.V</publisher><subject>A549 Cells ; Anti-cancer ; Antineoplastic Agents - pharmacology ; Calorimetry - methods ; Cell Line, Tumor ; Circular Dichroism - methods ; Combination therapy ; Cytotoxins - pharmacology ; DNA - drug effects ; DNA interaction ; Doxorubicin - pharmacology ; Drug Synergism ; Fluorescence ; Glibenclamide ; Glyburide - pharmacology ; Grove binding ; Hep G2 Cells ; Humans ; Molecular Docking Simulation - methods ; Spectrometry, Fluorescence - methods ; Thermodynamics</subject><ispartof>Journal of pharmaceutical and biomedical analysis, 2018-05, Vol.154, p.294-301</ispartof><rights>2018 Elsevier B.V.</rights><rights>Copyright © 2018 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-195109e22667d0b08c68c5d551f1e891c78a3c9483dc7f6c8ee3362b117e13403</citedby><cites>FETCH-LOGICAL-c356t-195109e22667d0b08c68c5d551f1e891c78a3c9483dc7f6c8ee3362b117e13403</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jpba.2018.03.025$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29567572$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Subramaniyam, Nithyananthan</creatorcontrib><creatorcontrib>Arumugam, Suyavaran</creatorcontrib><creatorcontrib>Ezthupurakkal, Preedia Babu</creatorcontrib><creatorcontrib>Ariraman, Subastri</creatorcontrib><creatorcontrib>Biswas, Indrani</creatorcontrib><creatorcontrib>Muthuvel, Suresh Kumar</creatorcontrib><creatorcontrib>Balakrishnan, Aristatile</creatorcontrib><creatorcontrib>Alshammari, Ghedeir M.</creatorcontrib><creatorcontrib>Chinnasamy, Thirunavukkarasu</creatorcontrib><title>Unveiling anticancer potential of glibenclamide: Its synergistic cytotoxicity with doxorubicin on cancer cells</title><title>Journal of pharmaceutical and biomedical analysis</title><addtitle>J Pharm Biomed Anal</addtitle><description>[Display omitted] •Glibenclamide interacts with DNA through groove binding.•The spectrometric and electrochemical studies reveal direct interaction of Glibenclamide with DNA.•The interaction between Glibenclamide and B-form of DNA is thermodynamically favorable.•Glibenclamide synergistically enhances the cytotoxicity of Doxorubicin against HepG2 and A 549 cells. Drug repurposing has been an emerging therapeutic strategy, which involves exploration of a new therapeutic approach for the use of an existing drug. Glibenclamide (Gli) is an anti-diabetic sulfonylurea drug extensively used for the treatment of type-2 diabetes, it has also been shown to possess anti-proliferative effect against several types of tumors. The present study was executed to understand the mechanisms underlying the interaction of Gli with DNA under physiological conditions. The binding mechanism of Gli with DNA was scrutinized by UV–vis absorption spectroscopy and fluorescence emission spectroscopy. The conformational changes and electrochemical properties were analyzed by circular dichroism spectroscopy and cyclic voltammetry. Isothermal titration calorimetry was employed to examine the thermodynamic changes and molecular docking technique used to analyze the interaction mode of Gli with DNA. The spectroscopic studies revealed that Gli interacts with DNA through groove binding mode. Further, isothermal titration calorimetry depicted a stronger mode of interaction favorably groove-binding. Recently, systemic combination therapy has shown significant promise in inhibiting multiple targets simultaneously yielding high therapeutic competence with lesser side effects. With this concern, we intended to study the combined cytotoxicity of Gli with doxorubicin (Dox). The results of MTT assay and acridine orange (AO)/ethidium bromide (EtBr) staining showed synergistic cytotoxicity of Gli + Dox combination on HepG2 &amp; A549 cells. The present study documents the intricate mechanism of Gli–DNA interaction and delivers a multifaceted access for chemotherapy by Gli + Dox combination.</description><subject>A549 Cells</subject><subject>Anti-cancer</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Calorimetry - methods</subject><subject>Cell Line, Tumor</subject><subject>Circular Dichroism - methods</subject><subject>Combination therapy</subject><subject>Cytotoxins - pharmacology</subject><subject>DNA - drug effects</subject><subject>DNA interaction</subject><subject>Doxorubicin - pharmacology</subject><subject>Drug Synergism</subject><subject>Fluorescence</subject><subject>Glibenclamide</subject><subject>Glyburide - pharmacology</subject><subject>Grove binding</subject><subject>Hep G2 Cells</subject><subject>Humans</subject><subject>Molecular Docking Simulation - methods</subject><subject>Spectrometry, Fluorescence - methods</subject><subject>Thermodynamics</subject><issn>0731-7085</issn><issn>1873-264X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1vEzEQhi0EomnhD3BAPnLZxWOvPxZxQRXQSpW4UImbteudDY42drCdtvn3OCRw5GSN9byvZh5C3gBrgYF6v2k3u3FoOQPTMtEyLp-RFRgtGq66H8_JimkBjWZGXpDLnDeMMQl995Jc8F4qLTVfkXAfHtAvPqzpEIp3Q3CY6C4WrNOw0DjT9eJHDG4Ztn7CD_S2ZJoPAdPa5xqg7lBiiU_e-XKgj778pFN8imk_1p9AY6DnTofLkl-RF_OwZHx9fq_I_ZfP369vmrtvX2-vP901TkhVGuglsB45V0pPbGTGKePkJCXMgKYHp80gXN8ZMTk9K2cQhVB8BNAIomPiirw79e5S_LXHXOzW5-MGQ8C4z_bojIGATlWUn1CXYs4JZ7tLfjukgwVmj57txh49_8lYJmz1XENvz_37cYvTv8hfsRX4eAKwXvngMdnsfLWIk0_oip2i_1__b3pfkDo</recordid><startdate>20180530</startdate><enddate>20180530</enddate><creator>Subramaniyam, Nithyananthan</creator><creator>Arumugam, Suyavaran</creator><creator>Ezthupurakkal, Preedia Babu</creator><creator>Ariraman, Subastri</creator><creator>Biswas, Indrani</creator><creator>Muthuvel, Suresh Kumar</creator><creator>Balakrishnan, Aristatile</creator><creator>Alshammari, Ghedeir M.</creator><creator>Chinnasamy, Thirunavukkarasu</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20180530</creationdate><title>Unveiling anticancer potential of glibenclamide: Its synergistic cytotoxicity with doxorubicin on cancer cells</title><author>Subramaniyam, Nithyananthan ; Arumugam, Suyavaran ; Ezthupurakkal, Preedia Babu ; Ariraman, Subastri ; Biswas, Indrani ; Muthuvel, Suresh Kumar ; Balakrishnan, Aristatile ; Alshammari, Ghedeir M. ; Chinnasamy, Thirunavukkarasu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-195109e22667d0b08c68c5d551f1e891c78a3c9483dc7f6c8ee3362b117e13403</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>A549 Cells</topic><topic>Anti-cancer</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Calorimetry - methods</topic><topic>Cell Line, Tumor</topic><topic>Circular Dichroism - methods</topic><topic>Combination therapy</topic><topic>Cytotoxins - pharmacology</topic><topic>DNA - drug effects</topic><topic>DNA interaction</topic><topic>Doxorubicin - pharmacology</topic><topic>Drug Synergism</topic><topic>Fluorescence</topic><topic>Glibenclamide</topic><topic>Glyburide - pharmacology</topic><topic>Grove binding</topic><topic>Hep G2 Cells</topic><topic>Humans</topic><topic>Molecular Docking Simulation - methods</topic><topic>Spectrometry, Fluorescence - methods</topic><topic>Thermodynamics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Subramaniyam, Nithyananthan</creatorcontrib><creatorcontrib>Arumugam, Suyavaran</creatorcontrib><creatorcontrib>Ezthupurakkal, Preedia Babu</creatorcontrib><creatorcontrib>Ariraman, Subastri</creatorcontrib><creatorcontrib>Biswas, Indrani</creatorcontrib><creatorcontrib>Muthuvel, Suresh Kumar</creatorcontrib><creatorcontrib>Balakrishnan, Aristatile</creatorcontrib><creatorcontrib>Alshammari, Ghedeir M.</creatorcontrib><creatorcontrib>Chinnasamy, Thirunavukkarasu</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of pharmaceutical and biomedical analysis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Subramaniyam, Nithyananthan</au><au>Arumugam, Suyavaran</au><au>Ezthupurakkal, Preedia Babu</au><au>Ariraman, Subastri</au><au>Biswas, Indrani</au><au>Muthuvel, Suresh Kumar</au><au>Balakrishnan, Aristatile</au><au>Alshammari, Ghedeir M.</au><au>Chinnasamy, Thirunavukkarasu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Unveiling anticancer potential of glibenclamide: Its synergistic cytotoxicity with doxorubicin on cancer cells</atitle><jtitle>Journal of pharmaceutical and biomedical analysis</jtitle><addtitle>J Pharm Biomed Anal</addtitle><date>2018-05-30</date><risdate>2018</risdate><volume>154</volume><spage>294</spage><epage>301</epage><pages>294-301</pages><issn>0731-7085</issn><eissn>1873-264X</eissn><abstract>[Display omitted] •Glibenclamide interacts with DNA through groove binding.•The spectrometric and electrochemical studies reveal direct interaction of Glibenclamide with DNA.•The interaction between Glibenclamide and B-form of DNA is thermodynamically favorable.•Glibenclamide synergistically enhances the cytotoxicity of Doxorubicin against HepG2 and A 549 cells. Drug repurposing has been an emerging therapeutic strategy, which involves exploration of a new therapeutic approach for the use of an existing drug. Glibenclamide (Gli) is an anti-diabetic sulfonylurea drug extensively used for the treatment of type-2 diabetes, it has also been shown to possess anti-proliferative effect against several types of tumors. The present study was executed to understand the mechanisms underlying the interaction of Gli with DNA under physiological conditions. The binding mechanism of Gli with DNA was scrutinized by UV–vis absorption spectroscopy and fluorescence emission spectroscopy. The conformational changes and electrochemical properties were analyzed by circular dichroism spectroscopy and cyclic voltammetry. Isothermal titration calorimetry was employed to examine the thermodynamic changes and molecular docking technique used to analyze the interaction mode of Gli with DNA. The spectroscopic studies revealed that Gli interacts with DNA through groove binding mode. Further, isothermal titration calorimetry depicted a stronger mode of interaction favorably groove-binding. Recently, systemic combination therapy has shown significant promise in inhibiting multiple targets simultaneously yielding high therapeutic competence with lesser side effects. With this concern, we intended to study the combined cytotoxicity of Gli with doxorubicin (Dox). The results of MTT assay and acridine orange (AO)/ethidium bromide (EtBr) staining showed synergistic cytotoxicity of Gli + Dox combination on HepG2 &amp; A549 cells. The present study documents the intricate mechanism of Gli–DNA interaction and delivers a multifaceted access for chemotherapy by Gli + Dox combination.</abstract><cop>England</cop><pub>Elsevier B.V</pub><pmid>29567572</pmid><doi>10.1016/j.jpba.2018.03.025</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0731-7085
ispartof Journal of pharmaceutical and biomedical analysis, 2018-05, Vol.154, p.294-301
issn 0731-7085
1873-264X
language eng
recordid cdi_proquest_miscellaneous_2018013146
source MEDLINE; Access via ScienceDirect (Elsevier)
subjects A549 Cells
Anti-cancer
Antineoplastic Agents - pharmacology
Calorimetry - methods
Cell Line, Tumor
Circular Dichroism - methods
Combination therapy
Cytotoxins - pharmacology
DNA - drug effects
DNA interaction
Doxorubicin - pharmacology
Drug Synergism
Fluorescence
Glibenclamide
Glyburide - pharmacology
Grove binding
Hep G2 Cells
Humans
Molecular Docking Simulation - methods
Spectrometry, Fluorescence - methods
Thermodynamics
title Unveiling anticancer potential of glibenclamide: Its synergistic cytotoxicity with doxorubicin on cancer cells
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T11%3A05%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Unveiling%20anticancer%20potential%20of%20glibenclamide:%20Its%20synergistic%20cytotoxicity%20with%20doxorubicin%20on%20cancer%20cells&rft.jtitle=Journal%20of%20pharmaceutical%20and%20biomedical%20analysis&rft.au=Subramaniyam,%20Nithyananthan&rft.date=2018-05-30&rft.volume=154&rft.spage=294&rft.epage=301&rft.pages=294-301&rft.issn=0731-7085&rft.eissn=1873-264X&rft_id=info:doi/10.1016/j.jpba.2018.03.025&rft_dat=%3Cproquest_cross%3E2018013146%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2018013146&rft_id=info:pmid/29567572&rft_els_id=S0731708517329448&rfr_iscdi=true